AU2406299A - Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect - Google Patents

Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect

Info

Publication number
AU2406299A
AU2406299A AU24062/99A AU2406299A AU2406299A AU 2406299 A AU2406299 A AU 2406299A AU 24062/99 A AU24062/99 A AU 24062/99A AU 2406299 A AU2406299 A AU 2406299A AU 2406299 A AU2406299 A AU 2406299A
Authority
AU
Australia
Prior art keywords
action
therapeutic effect
long lasting
rapid onset
drug formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24062/99A
Inventor
Georges Bruttmann
Rene Kerouac
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTRAPHARM Inc
Original Assignee
CENTRAPHARM Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2243983 external-priority patent/CA2243983A1/en
Application filed by CENTRAPHARM Inc filed Critical CENTRAPHARM Inc
Publication of AU2406299A publication Critical patent/AU2406299A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
AU24062/99A 1998-02-12 1999-02-11 Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect Abandoned AU2406299A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7454898P 1998-02-12 1998-02-12
US60074548 1998-02-12
CA2243983 1998-09-17
CA 2243983 CA2243983A1 (en) 1998-02-12 1998-09-17 Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
PCT/CA1999/000095 WO1999040898A2 (en) 1998-02-12 1999-02-11 Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect

Publications (1)

Publication Number Publication Date
AU2406299A true AU2406299A (en) 1999-08-30

Family

ID=25680401

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24062/99A Abandoned AU2406299A (en) 1998-02-12 1999-02-11 Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect

Country Status (2)

Country Link
AU (1) AU2406299A (en)
WO (1) WO1999040898A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2355406A (en) * 1999-10-23 2001-04-25 Alkaloid Ad A sub-lingual dosage form comprising a morphine salt
ITRM20030288A1 (en) * 2003-06-10 2004-12-11 Valerio Cioli SUBLINGUAL ADMINISTRATION OF NON STEROID INFLAMMATORY (NSAID)
JP2007533697A (en) * 2004-04-22 2007-11-22 デュオコート エービー Pharmaceutical composition for glucocorticoid emergency treatment
CA2593492C (en) * 2005-01-19 2011-12-13 Neurohealing Pharmaceuticals, Inc. Methods and compositions for decreasing saliva production
EP1810678A1 (en) 2006-01-19 2007-07-25 Holger Lars Hermann Use of morphine and naloxone for drug substitution
US20100179215A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20080058408A1 (en) 2006-05-19 2008-03-06 Rogowski Roberta L Low-dose doxepin for treatment of sleep disorders in elderly patients
US20100179214A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
CA2687124A1 (en) * 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia
WO2007142810A2 (en) 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
ITMI20061117A1 (en) * 2006-06-09 2007-12-10 Michele Bonanomi A PHARMACEUTICAL COMPOSITION FOR THE SUBLINGUAL ADMINISTRATION OF VACCINI METHOD FOR ITS PREPARATION AND USES
US7915307B2 (en) 2006-07-20 2011-03-29 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
WO2008052139A2 (en) 2006-10-25 2008-05-02 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
US20110077200A1 (en) 2006-12-06 2011-03-31 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
WO2008128115A2 (en) 2007-04-13 2008-10-23 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations
FR2926722B1 (en) * 2008-01-25 2010-09-03 Substipharm Dev APPROPRIATE PHARMACEUTICAL FORMULATION FOR THE PREPARATION OF ORODISPERSIBLE PRELOISOLONE TABLETS
US20130203721A1 (en) 2010-02-22 2013-08-08 Lupin Limited Taste-masked powder for suspension compositions of methylprednisolone
NZ732075A (en) 2014-10-29 2022-09-30 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding
US20170216220A1 (en) 2016-02-03 2017-08-03 Intelgenx Corp. Loxapine film oral dosage form
US9949934B1 (en) * 2016-10-20 2018-04-24 Intelgenx Corp. Device and method of treating conditions associated with neuroinflammation
AU2018250398B2 (en) 2017-07-12 2019-02-28 Samson Clinical Pty Ltd Promoting hair growth and treatment of hair loss or excessive hair shedding

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1279214A (en) * 1970-01-22 1972-06-28 Forest Laboratories Long-acting oral carrier
FR2619718B1 (en) * 1987-09-02 1991-07-12 Medibrevex NOVEL GALENIC FORMS OF BETA-2-MIMETICS FOR PER- AND SUBLINGUAL ADMINISTRATION
FR2621483B1 (en) * 1987-10-08 1991-09-20 Medibrevex NOVEL GALENIC FORMS OF CORTICOIDS FOR PER- AND SUBLINGUAL ADMINISTRATION AND THEIR PREPARATION PROCESS
FR2640138B1 (en) * 1988-12-13 1993-08-20 Medibrevex METHOD FOR OBTAINING GALENIC FORMS BASED ON ACTIVE PHARMACEUTICAL COMPOUNDS FOR PER- AND SUBLINGUAL ADMINISTRATION
JP2000505090A (en) * 1996-07-11 2000-04-25 ファーマーク、ニーダーランド、ベスローテン、フェンノートシャップ Inclusion complexes containing indole-selective serotonin agonists

Also Published As

Publication number Publication date
WO1999040898A3 (en) 1999-11-04
WO1999040898A2 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
AU2406299A (en) Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
AU3445697A (en) New use of xylitol and pharmaceutical compositions therefor
EP1227821A4 (en) Therapeutic compositions and methods of use thereof
HUP0004802A3 (en) Nicotine compositions and methods of formulation thereof
AU4217499A (en) Composition having therapeutic and/or nutritionally active substituent
AU4300701A (en) Methods and compositions for administration of therapeutic reagents
IL141429A0 (en) Compositions and methods for treatment of mitochondrial diseases
AU6513298A (en) Therapeutic compositions
AU5315898A (en) Compositions for disinfection of skin and mucous membrane
AU1041599A (en) Therapeutic uses of triazolo-pyridazine derivatives
AU8905098A (en) Skin care compositions and use
GB2323531B (en) Therapeutic formulations
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein
IL133053A0 (en) Local delivery of long lasting therapeutic agents
AU7907300A (en) Novel combination of loteprednol and antihistamines
AU3656397A (en) Formulations of vesicant drugs and methods of use thereof
AU2180097A (en) Composition for prevention and treatment of periodontal diseases
AU1164601A (en) Therapeutic use and formulation
AU1262501A (en) Compositions for transdermal and transmucosal administration of therapeutic agents
AU2002241611A1 (en) Orally-bioavailable formulations of fentanyl and congeners thereof
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
AU5729099A (en) Use of cyclopentabenzofuran-derivatives for combating nf-KappaB-dependent diseases
AU3501700A (en) Human endokine alpha and methods of use
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU9588398A (en) Vaccine compositions and methods of enhancing vaccine efficacy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase